Evaluation of effect of Curcumin on the serum levels of 12-inflammatory cytokines & highly sensitive C-reactive protei

Phase 3

Conditions: AFLD.
nonalcoholic steatohepatitis
K75.8

Registration Number: IRCT2015052322381N1

Lead Sponsor: eyshabour University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 43

Inclusion Criteria

Age between 18–65 years
The diagnosis of fatty liver using ultrasound

Exclusion Criteria

Women with pregnancy/lactation
Alcoholic liver disease
Taking anti-inflammatory drugs such as Curtin
Acute or chronic liver disorders such as viral (hepatitis B and C) and autoimmune hepatitis
Metabolic liver disorders including hemochromatosis and Wilson’s disease, Budd–Chiari syndrome
Having other medical disorders such as cardiovascular diseases and cancer
Taking liver enzyme enhancement drugs
Have severe heart and lung disease
Hypothyroidism and hyperthyroidism
Alpha-1 antitrypsin deficiency
Celiac disease

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AFLD grade. Timepoint: Before intervention and two months after intervention. Method of measurement: Sonography.;Tumor necrosis factor alpha (TNF-a). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;High-sensitivity C-reactive Protein (hs-CRP). Timepoint: Before intervention and two months after intervention. Method of measurement: Auto-analyzer BT-2000.;Interleukin 6 (IL-6). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Interleukin 10 (IL-10). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.;Monocyte Chemoattractant Protein-1 (MCP-1). Timepoint: Before intervention and two months after intervention. Method of measurement: ELISA.

Secondary Outcome Measures